Steady-state pharmacokinetics of conjugated equine estrogens in healthy, postmenopausal women

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 53, Issue 2, 2008, Pages 97-101

  Mayer, Philip ^a   Tse, Susanna ^a   Sendi, Mary ^a   Bourg, Dale ^a   Morrison, Dennis ^a  

^a NONE

Author keywords

Conjugated; Estrogens; Pharmacokinetics; Postmenopause; Premarin

Indexed keywords

CONJUGATED ESTROGEN; DELTA 8,9 DEHYDROESTRONE; EQUILIN; ESTRADIOL; ESTROGEN; ESTRONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EXPOSURE; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEADY STATE; TABLET; BLOOD; DRUG EFFECT; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE;

EID: 44049096812     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712
2. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
3. 3H]equilin sulfate after oral and intravenous administration in normal postmenopausal women and men. J Clin Endocrinol Metab 1989;68:757-765
4. Bhavnani BR: Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: Chemistry and metabolism. Proc Soc Exp Biol Med 1998;217:6-16
5. Bhavnani BR, Sarda IR, Woolever CA: Radioimmunoassay of plasma equilin and estrone in postmenopausal women after the administration of Premarin. J Clin Endocrinol Metab 1981;52:741-747
6. United States Pharmacopeia: Conjugated estrogens. USP29-NF24, 2006, p 851
7. US Department of Health and Human Services: FDA statement on generic Premarin. Bethesda, Maryland, Food and Drug Administration, 1997, pp 97-112
8. US Department of Health and Human Services: FDA backgrounder on conjugated estrogens. Bethesda, Maryland, Food and Drug Administration, 2005
9. Woodcock J: Memorandum: Approvability of a synthetic generic version of Premarin, 1997. Available at http:// www.fda.gov/cder/news/celetterjw.htm. Accessed on Feb. 20, 2007
10. Dey M, Lyttle CR, Pickar JH: Recent insights into the varying activity of estrogens. Maturitas (suppl 2) 2000;34:S25-S33
11. Ritter S: Premarin. Chem Eng News 2005;83:100-102
12. Dorfman RI, Dorfman AS: Estrogen assays using the rat uterus. Endocrinology 1954;55:65-69
13. Troy SM, Hicks DR, Parker VD, et al: Differences in pharmacokinetics and comparative bioavailability between Premarin® and Estratab® in healthy postmenopausal women. Curr Ther Res 1994;55:359-372
14. Bhavnani BR, Nisker JA, Martin J, et al: Comparison of pharmacokinetics of a conjugated equine estrogen preparation (premarin) and a synthetic mixture of estrogens (C.E.S.) in postmenopausal women. J Soc Gynecol Invest 2000;7:175-183
15. Arteaga E, Villaseca P: Pharmacokinetic comparison between Conpremin® (Premarin®) and a generic preparation of conjugated estrogens. Climacteric 1998;1:284-289
16. Bhavnani BR, Cecutti A: Metabolic clearance rate of equilin sulfate and its conversion to plasma equilin, conjugated and unconjugated equilenin, 17β-dihydroequilin, and 17β-dihydroequilenin in normal postmenopausal women and men under steady state conditions. J Clin Endocrinol Metab 1993;77:1269-1274
17. Bhavnani BR, Cerulath A, Cecutti A: Pharmacokinetics and pharmacodynamics of delta-8 estrone (abstr). J Soc Gynecol Invest 1996;3:364A
18. Bhavnani BR, Cecutti A: Pharmacokinetics of 17β-dihydroequilin sulfate and 17β-dihydroequilin in normal postmenopausal women. J Clin Endocrinol Metab 1994;78: 197-204
19. Scott RT, Ross B, Anderson C, et al: Pharmacokinetics and percutaneous estradiol: A crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991;77:758-764
20. Nichols KC, Schenkel L, Benson H: 17β-estradiol for post-menopausal estrogen replacement therapy. Obstet Gynecol Surv (suppl) 1984;39:230-245